DK1815247T3 - Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet - Google Patents
Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitetInfo
- Publication number
- DK1815247T3 DK1815247T3 DK05851365.6T DK05851365T DK1815247T3 DK 1815247 T3 DK1815247 T3 DK 1815247T3 DK 05851365 T DK05851365 T DK 05851365T DK 1815247 T3 DK1815247 T3 DK 1815247T3
- Authority
- DK
- Denmark
- Prior art keywords
- efficacy
- monitoring
- methods
- therapeutic use
- transferase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62520404P | 2004-11-05 | 2004-11-05 | |
| US70807505P | 2005-08-12 | 2005-08-12 | |
| PCT/US2005/039948 WO2006052718A2 (en) | 2004-11-05 | 2005-11-02 | Farnesyltransferase inhibitors for treating sepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1815247T3 true DK1815247T3 (da) | 2013-03-11 |
Family
ID=35840451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05851365.6T DK1815247T3 (da) | 2004-11-05 | 2005-11-02 | Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet |
| DK11158145.0T DK2362218T3 (da) | 2004-11-05 | 2005-11-02 | Fremgangsmåder til overvågning af effektiviteten af farnesyltransferaseinhibitorer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11158145.0T DK2362218T3 (da) | 2004-11-05 | 2005-11-02 | Fremgangsmåder til overvågning af effektiviteten af farnesyltransferaseinhibitorer |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20060111398A1 (da) |
| EP (2) | EP2362218B1 (da) |
| DK (2) | DK1815247T3 (da) |
| ES (2) | ES2403060T3 (da) |
| HK (1) | HK1110651A1 (da) |
| HR (1) | HRP20130399T1 (da) |
| ME (1) | ME01509B (da) |
| PL (2) | PL1815247T3 (da) |
| PT (2) | PT1815247E (da) |
| RS (1) | RS52741B (da) |
| SI (1) | SI2362218T1 (da) |
| WO (1) | WO2006052718A2 (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | TREATMENT OF SYNUCLEINOPATHIES |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US20050288298A1 (en) * | 2004-03-18 | 2005-12-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| CA2743717A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| BRPI0921113A2 (pt) * | 2008-11-13 | 2016-02-16 | Link Medicine Corp | tratamento de proteinopatias usando um inibidor de farnesil transferase. |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| AU2013331505A1 (en) | 2012-10-16 | 2015-04-30 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ROR-gamma-t |
| WO2014062655A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt |
| CA2888210C (en) | 2012-10-16 | 2021-02-09 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| EP3057422B1 (en) | 2013-10-15 | 2019-05-15 | Janssen Pharmaceutica NV | Quinolinyl modulators of ror(gamma)t |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｒｏｒγｔのアルキル結合キノリニルモジュレーター |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US10564162B2 (en) * | 2014-07-02 | 2020-02-18 | Bionomics Limited | Predictive biomarkers |
| EP3226973A4 (en) * | 2014-12-04 | 2018-05-30 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| ES2844848T3 (es) | 2015-04-21 | 2021-07-22 | Eiger Biopharmaceuticals Inc | Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir |
| CA2985123C (en) | 2015-08-17 | 2021-04-13 | Antonio Gualberto | Methods of treating cancer patients with farnesyltransferase inhibitors |
| CN105510187B (zh) * | 2016-01-28 | 2018-01-23 | 青岛啤酒股份有限公司 | 用于啤酒糖化过程中快速判定麦汁发酵度的方法 |
| MY190861A (en) | 2016-11-03 | 2022-05-12 | Kura Oncology Inc | Farnesyltransferase inhibitors for use in methods of treating cancer |
| JP2023521468A (ja) * | 2020-04-16 | 2023-05-24 | エフ． ホフマン－ラ ロシュ アーゲー | ビフェニル誘導体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6117432A (en) | 1995-04-20 | 2000-09-12 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
| TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| DE69620445T2 (de) | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica N.V., Beerse | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| EP0946565B1 (en) | 1996-12-20 | 2003-10-15 | Tovarischestvo S Ogranichennoi Otvetstvennostju "Tabifarm" | Method and device for production of lyophilized hydrochloride-1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12-olide |
| TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| GB2323783A (en) | 1997-04-02 | 1998-10-07 | Ferring Bv Group Holdings | Inhibitors of farnesyl protein transferase |
| EP0977750B1 (en) | 1997-04-25 | 2007-07-04 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
| CN1196336C (zh) | 1998-03-05 | 2005-04-06 | 第一程式管理有限公司 | 数据通信系统 |
| US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
| AU5086499A (en) | 1998-07-01 | 2000-01-24 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
| BR9911869A (pt) | 1998-07-06 | 2001-03-27 | Janssen Pharmaceutica Nv | Inibidores da transferase da proteìna farnesil para o tratamento das artropatias |
| OA11645A (en) | 1998-08-27 | 2004-11-16 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents. |
| DE69923849T2 (de) | 1998-08-27 | 2006-01-12 | Pfizer Products Inc., Groton | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
| TW531533B (en) | 1998-12-23 | 2003-05-11 | Janssen Pharmaceutica Nv | 1,2-annelated quinoline derivatives having farnesyl transferase and geranylgeranyl transferase inhibiting activity |
| GB0023915D0 (en) | 2000-09-29 | 2000-11-15 | Inst Of Ophthalmology | Treatment of neuroinflammatory disease |
| DK1339407T3 (da) | 2000-11-28 | 2006-08-14 | Janssen Pharmaceutica Nv | Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom |
| JP2004526776A (ja) | 2001-04-25 | 2004-09-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 悪液質を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤 |
| BR0316231A (pt) * | 2002-11-12 | 2005-10-04 | Becton Dickinson Co | Métodos para determinar o estado de sepsia para prognosticar o começo de sepsia e para diagnosticar a sìndrome de resposta inflamatória sistêmica em um indivìduo e para isolar um biomarcador, perfil biomarcador r kit |
-
2005
- 2005-11-02 DK DK05851365.6T patent/DK1815247T3/da active
- 2005-11-02 ES ES05851365T patent/ES2403060T3/es active Active
- 2005-11-02 WO PCT/US2005/039948 patent/WO2006052718A2/en active Application Filing
- 2005-11-02 RS RS20130146A patent/RS52741B/en unknown
- 2005-11-02 ME MEP-2013-46A patent/ME01509B/me unknown
- 2005-11-02 SI SI200531911T patent/SI2362218T1/sl unknown
- 2005-11-02 EP EP11158145.0A patent/EP2362218B1/en active Active
- 2005-11-02 US US11/265,445 patent/US20060111398A1/en not_active Abandoned
- 2005-11-02 PL PL05851365T patent/PL1815247T3/pl unknown
- 2005-11-02 PL PL11158145T patent/PL2362218T3/pl unknown
- 2005-11-02 PT PT58513656T patent/PT1815247E/pt unknown
- 2005-11-02 DK DK11158145.0T patent/DK2362218T3/da active
- 2005-11-02 ES ES11158145.0T patent/ES2522830T3/es active Active
- 2005-11-02 PT PT111581450T patent/PT2362218E/pt unknown
- 2005-11-02 EP EP05851365A patent/EP1815247B1/en active Active
-
2008
- 2008-02-05 HK HK08101410.2A patent/HK1110651A1/xx unknown
-
2009
- 2009-02-02 US US12/363,810 patent/US20110195419A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,200 patent/US20120196766A1/en not_active Abandoned
-
2013
- 2013-05-08 HR HRP20130399TT patent/HRP20130399T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006052718A3 (en) | 2007-06-28 |
| PL2362218T3 (pl) | 2015-02-27 |
| PL1815247T3 (pl) | 2013-08-30 |
| WO2006052718A2 (en) | 2006-05-18 |
| HRP20130399T1 (hr) | 2013-06-30 |
| US20120196766A1 (en) | 2012-08-02 |
| EP2362218B1 (en) | 2014-08-27 |
| ME01509B (me) | 2014-04-20 |
| ES2403060T3 (es) | 2013-05-13 |
| EP1815247B1 (en) | 2013-02-20 |
| US20060111398A1 (en) | 2006-05-25 |
| HK1110651A1 (en) | 2008-07-18 |
| WO2006052718A8 (en) | 2007-02-08 |
| EP2362218A3 (en) | 2011-10-26 |
| EP2362218A2 (en) | 2011-08-31 |
| RS52741B (en) | 2013-08-30 |
| ES2522830T3 (es) | 2014-11-18 |
| PT1815247E (pt) | 2013-04-23 |
| SI2362218T1 (sl) | 2014-12-31 |
| EP1815247A2 (en) | 2007-08-08 |
| DK2362218T3 (da) | 2014-11-17 |
| US20110195419A1 (en) | 2011-08-11 |
| PT2362218E (pt) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1815247T3 (da) | Terapeutisk anvendelse af farnesyltransferaseinhibitorer og fremgangsmåder til overvågning af deres effektivitet | |
| DK1931645T3 (da) | N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase | |
| DK1962895T3 (da) | TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST | |
| CY2013042I1 (el) | Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog | |
| DK1791852T3 (da) | C-aryl glucosid -SGLT2-inhibitorer og metode til deres fremstilling | |
| CY2014011I2 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
| DK2041129T3 (da) | Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse | |
| DK1913157T3 (da) | EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling | |
| DK2114531T3 (da) | Punktpropper og fremgangsmåder til indgivelse af terapeutiske midler | |
| DK1771446T3 (da) | Azaindolinhibitorer af MTP og APOB | |
| DK2439205T3 (da) | Carboxamidforbindelser og deres anvendelse som calpaininhibitorer | |
| DK2073811T3 (da) | Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme | |
| NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
| DK2046373T3 (da) | Krystalliseret oxalatdecarboxylase og fremgangsmåder til anvendelse | |
| DK1606283T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
| IS8597A (is) | Samsetningar rísedrónats og aðferðir við notkun þess | |
| DK2089361T3 (da) | Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse | |
| IS8037A (is) | P38-hindrar og aðferðir til notkunar þeirra | |
| IS7977A (is) | Samsetningar og aðferð til samsettra meðferðar | |
| DK2099447T3 (da) | Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer | |
| ATE521604T1 (de) | N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek | |
| DK2132194T3 (da) | Substituerede isoquinoliner og deres anvendelse som Rho-kinase inhibitorer | |
| IL180738A0 (en) | Inhibitors of hcv replication | |
| DK1776181T3 (da) | System og fremgangsmåde til fluidtilførsel | |
| DK2379096T3 (da) | TFPI-inhibitorer og fremgangsmåder til anvendelse |